Number of the records: 1

Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?

SYSNO ASEP	0350402
Document Type	J - Journal Article
R&D Document Type	Journal Article
Subsidiary J	Článek ve WOS
Title	Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?
Author(s)	Smržová, J. (CZ) Urbánek, Tomáš (PSU-E)_{RID, ORCID, SAI}
Number of authors	2
Source Title	Kidney & Blood Pressure Research. - : Karger - ISSN 1420-4096 Roč. 33, č. 5 (2010), s. 333-342
Number of pages	10 s.
Publication form	WWW - WWW
Language	eng - English
Country	CH - Switzerland
Keywords	Cinacalcet ; Itching ; Phosphate binders
Subject RIV	FE - Other Internal Medicine Disciplines
CEZ	AV0Z70250504 - PSU-E (2005-2011)
UT WOS	000284644200001
DOI	10.1159/000317935
Annotation	The cost and effectiveness patterns in the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients in the Czech Republic are unknown. 52 dialysis patients from 17 centers were followed up in a multicenter prospective study of laboratory and clinical responses to 12-month cinacalcet treatment. Treatment patterns and cost (including phosphate binders, vitamin D, and cinacalcet) were evaluated. The mean s-Ca, s-P, Ca×P, and iPTH dropped significantly. The mean cinacalcet dose reached 44.1 ± 23.0 mg/day after 12 months. Itching intensity decreased significantly. The direct cost of daily SHPT treatment rose significantly from EUR 8.77 ± 9.59 to 20.62 ± 9.22. Cinacalcet decreased elevated s-Ca, s-P, Ca×P, and iPTH, alleviated itching, and significantly raised the SHPT treatment cost. A minority of patients reached K/DOQI targets, especially due to poor phosphate control caused by insufficient phosphate binder treatment, cinacalcet underdosing, and advanced SHPT.
Workplace	Institute of Psychology
Contact	Štěpánka Halamová, Halamova@praha.psu.cas.cz, Tel.: 222 222 096
Year of Publishing	2011

Number of the records: 1